Last update 24 May 2025

HER2/Neu GP2 vaccine (Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology)

Overview

Basic Info

Drug Type
Shared antigen vaccine
Synonyms
GP2 + GM-CSF, GP2 peptide + GMCSF vaccine, GP2 peptide NuGenerex ImmunoOncology
+ [3]
Target
Action
modulators, stimulants
Mechanism
HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators), Immunostimulants
Inactive Indication
Active Organization
Inactive Organization
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 3
United States
11 Aug 2022
HER2 Positive Breast CancerPhase 3
France
11 Aug 2022
HER2 Positive Breast CancerPhase 3
Germany
11 Aug 2022
HER2 Positive Breast CancerPhase 3
Italy
11 Aug 2022
HER2 Positive Breast CancerPhase 3
Poland
11 Aug 2022
HER2 Positive Breast CancerPhase 3
Spain
11 Aug 2022
Node-positive breast cancerPhase 2
United States
01 Jan 2007
Node-positive breast cancerPhase 2
United States
01 Jan 2007
Node-positive breast cancerPhase 2
Germany
01 Jan 2007
Node-positive breast cancerPhase 2
Germany
01 Jan 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(HLA-A*02 patients)
eyjiodlsou(nasubdnjef) = The number of patients experiencing an immune response increased over time from baseline through the 4th to 6th month vaccinations in both HLA-A*02 and non-HLA-A*02 arms. fhzctqcrpu (bzgclltlzd )
Positive
02 Apr 2025
(non-HLA-A*02 patients)
Phase 3
-
kpqobfbffd(xpxhyvnmwe) = wltlmtuxli iiifvrdquc (afgmblxuxq )
Positive
10 Feb 2025
Placebo
-
Phase 3
-
djkucsmzlx(fjjiovjmnv) = None astezepbdb (eytezknmfc )
Positive
14 Feb 2024
Phase 2
HER2 Positive Breast Cancer
Adjuvant
HER2 Positive
180
zymxjpxeji(towyzuuesg) = krsaiubeyo hutdgmptjl (rbzwkdrswa )
Positive
02 Jun 2022
zymxjpxeji(towyzuuesg) = zrqnofodva hutdgmptjl (rbzwkdrswa )
Phase 2
Metastatic breast cancer
HER2 positive | HER3 positive
180
rluxdhdnbh(ibnoczttby) = fjmavlpwfi qzhlscwnsc (weygnmnynp )
Positive
19 Apr 2022
GM-CSF
rluxdhdnbh(ibnoczttby) = fcnajlanil qzhlscwnsc (weygnmnynp )
Phase 2
180
GM-CSF+GP2
uovvjhduev(dcgqfkhycc) = gynlhjtijw lwvvxzsejs (huwikqmdue, 59.5 - 87.9)
Positive
15 Feb 2021
GM-CSF
uovvjhduev(dcgqfkhycc) = rxqzpdnvqn lwvvxzsejs (huwikqmdue, 60.1 - 88.2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free